You are here: Industry Insights > Rocket Pharmaceuticals

News List

Rocket Pharmaceuticals announces buildout of R&D and manufacturing facility to support development of gene therapy pipeline pharmaceutical-business-review
January 14, 2021
Rocket Pharmaceuticals, a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders, announces the Company’s plans for the buildout of its new Research and Development (R&D) and Chemistry ...
Forty Seven, Rocket collaborate on new treatment for Fanconi Anemia pharmaceutical-business-review
March 13, 2020
Forty Seven and Rocket Pharmaceuticals have entered into a research collaboration for evaluating a new treatment regimen in Fanconi Anemia, a rare paediatric disease.
Rocket Pharmaceuticals Announces Presentations at the American College of Cardiology 2019 Annual Meeting firstwordpharma
March 18, 2019
"RP-A501 is the first investigational gene therapy for Danon disease and has the potential to revolutionize the treatment of this devastating cardiomyopathy. We are excited to move RP-A501 into the clinic in the second quarter of 2019," concluded Dr. Schw
Rocket Pharmaceuticals Announces First Patient Dosed in Phase 1 Clinical Trial of RP-L102 in the U.S. firstwordpharma
March 13, 2019
Rocket Pharmaceuticals, Inc.(NASDAQ:RCKT) ("Rocket"), a leading U.S.-based multi-platform gene therapy company, today announces that the first patient has been dosed in the open-label, Phase 1 clinical trial of RP-L102, the Company's lentiviral vector (LV
Rocket Pharmaceuticals Announces Clearance of IND for RP-A501 Gene Therapy for Danon Disease firstwordpharma
January 23, 2019
In parallel with the Phase 1 clinical trial, the Company plans to publish a comprehensive literature review of Danon cases and conduct a retrospective chart review. In addition, the Company will initiate a prospective natural history study with enrollment